As shown in Table 1, in the analysis of clinical condition, comorbidity, and laboratory evaluations, there were statistically significant differences with hemorrhagic bullae (53.8% vs. 15.4%; p = 0.001), diabetes mellitus (76.9% vs. 41.4%; p = 0.004), peripheral artery disease (23.1% vs. 1.2%; p < 0.001), C-reactive protein level (191.9 mg/dL vs. 134.1 mg/dL), bacteremia (69.2% vs. 36.0%; p = 0.001), and Laboratory Risk Indicator for Necrotizing Fasciitis (LRINEC) score > 8 (61.5% vs. 36.7%; p < 0.001) between mortality in the late amputation and survival in the amputation groups. This evidence concerns the gene CRP and diabetes mellitus.